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The ubiquitin proteasome system (UPS) contributes to the
pathophysiology of neurodegenerative diseases, and it is
also a major determinant of synaptic protein degradation
and activity. Recent studies in rodents and in the fruit ﬂy
 
Drosophila
 
 have shown that the activity of the UPS is
involved in axonal degeneration. Increased knowledge of
the UPS in synaptic and axonal reactions may provide
novel drug targets for treatments of neuronal injuries and
neurodegenerative disorders.
 
Neurodegenerative diseases are characterized by the selective
loss of neurons due to aggregation of different intra- or
extracellular proteins (Bence et al., 2001). Apart from the
deleterious effects of the protein deposits on the nerve cell
soma, the axons and dendrites also degenerate in these diseases.
The functional changes observed early in neurodegenerative
disorders are reflected by alterations in synaptic dysfunctions
and loss of connectivity. Recent evidence indicates that the
degeneration of axons and synapses plays an important role
both in chronic diseases and after injuries. The molecular
mechanisms governing axonal degeneration and synaptic
maintenance are not fully understood, but a crucial role has
been ascribed to the activity of the UPS.
 
UPS and neurological disorders
 
Ubiquitin is a 76 aa–long protein that becomes attached to
other proteins through a multi-enzyme system (Weissman,
2001; Adams, 2003). The first step is the activation of
ubiquitin by an enzyme, E1, followed by transfer to an
ubiquitin conjugating enzyme, E2, and to the ubiquitin ligase,
E3 that covalently attaches the ubiquitin moiety to a lysine
residue on target proteins (Fig. 1 A). There are several E2
and many E3 enzymes that are specific for different protein
substrates that increase the diversity of this system. Reiteration
of the cycle produces polyubiquitin chains on target proteins
that are then degraded by the UPS to small peptides. At the
heart of the UPS is the 26S proteasome that consists of a
20S core particle and two 19S regulatory particles (Fig. 1 A).
Apart from ubiquitination, there are deubiquitination en-
zymes that replenish the cellular pool of ubiquitin and are
important for the proper function of the proteasome. Modi-
fications of protein substrates through attachment of a
monoubiquitin or polyubiquitin chain are important in
many cellular processes ranging form cell cycle control,
DNA repair, transcription, cell signaling, and regulation of
protein trafficking (Hicke, 2001; Weissman, 2001; Adams,
2003). In the nervous system, ubiquitination plays a role,
among others, in neuronal signaling, synapse formation and
function, and in different diseases (Hegde and DiAntonio,
2002; Ciechanover and Brundin, 2003).
It is becoming increasingly evident that altered activities
of the UPS are crucially involved in the pathophysiology of
Parkinson’s disease (PD), Huntington’s disease (HD), and
in spinocerebellar ataxia (Bence et al., 2001; Lindsten et al.,
2002; Ciechanover and Brundin, 2003). Mutations in 
 
parkin
 
,
encoding an ubiquitin-E3 ligase result in juvenile recessive
PD (Dawson and Dawson, 2003). 
 
 
 
-Synuclein, which is
mutated in some familiar forms of PD, is highly enriched
in presynaptic terminals and Lewy-bodies (Kaplan et al.,
2003). Recently, the higher than normal level of wild-type
 
 
 
-synuclein was found in a family with early onset PD, and
a contributing mechanism could be an insufficient clearance
by the UPS (Eriksen et al., 2003; Singleton et al., 2003).
Apart from PD, other neurodegenerative disorders also
display accumulation of mutated proteins in inclusion bod-
ies and aggregates in conjunction with ubiquitin (Lindsten
et al., 2002; Ciechanover and Brundin, 2003). The presence
of protein deposits has been amply demonstrated in neu-
ronal cell bodies, but less is known about their occurrence in
axons and synapses. Recent studies on HD and other PolyQ
diseases show that the respective mutated proteins can inter-
fere with axonal transport (Gunawardena et al., 2003;
Szebenyi et al., 2003). The Huntingtin protein involved in
HD also interacts with synaptic vesicles and proteins involved
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in neurotransmission (Song et al., 2003). In spinocerebellar
ataxia 1, there is an altered trafficking of glutamate receptor
subunits and PKC
 
 
 
 in Purkinje cells (Skinner et al., 2001).
Given the role of the UPS in disease pathophysiology, it is
important to study the key proteins in the axons and in the
synapses that may be altered in the different disorders.
 
UPS and the function of synapses
 
Synapses undergo large structural changes during matura-
tion and in response to neuronal activity. As shown by
Ehlers (2003), the UPS regulates the degradation of mole-
cules, belonging to the postsynaptic densities (PSDs) that
contain various receptors and scaffolding proteins. Synaptic
activity influences the ubiquitination and turnover of a sub-
set of PSD proteins, important for the control of synapse
function and maintenance (Ehlers, 2003). Results with 
 
Aply-
sia
 
 have shown that protein ubiquitination is important for
synaptic plasticity (Hegde and DiAntonio, 2002). Likewise,
the activity of the ubiquitin ligase, Ube3A, is crucial for
long-term potentiation in mouse hippocampus, and the
gene is mutated in Angelman’s syndrome, a human disorder
causing mental retardation (Miura et al., 2002). Together,
these studies show that the UPS and protein modifications
via ubiquitination play an important role in regulation of
synaptic maintenance and function in different organisms.
However, the time window and specific proteins regulated
by the UPS vary between different studies. In the work on
the PSD proteins, a time scale of 24–48 h was used. In this
time, the UPS acts on different targets, including ubiquiti-
nation of proteins controlling transcription or translation
that may indirectly influence protein abundance in the syn-
apse. In their study of the neuromuscular system in 
 
Drosoph-
ila
 
, Speese et al. (2003) noted a relatively short time window
for the degradation of synaptic proteins by the UPS. Using
drugs to inhibit the activity, in addition to genetic manipu-
lation of the proteasome, DUNC-13 was identified as a se-
lective target for UPS in the presynaptic terminal. Electro-
physiological recordings showed that proteasome inhibition
also enhanced synaptic efficacy and presynaptic transmitter
release. This data demonstrates that the activity of the UPS
locally regulates the levels of DUNC-13 and influences pre-
synaptic efficacy in 
 
Drosophila
 
. The correlative changes ob-
served in synaptic function and regulation of the DUNC-13
by the UPS also suggest that the levels of DUNC-13 may be
the crucial mediator for increased neurotransmitter release.
However, this functional link has so far not been directly
shown neither are other protein excluded as targets for the
UPS in this context.
Members of the UNC protein family are found in differ-
ent species, and are involved in synaptic vesicle priming and
regulation of neurotransmitter release. It would be impor-
tant to study whether the mouse homologue MUNC-1,
shown to be important for proper function of glutamatergic
synaptic vesicles (Augustin et al., 1999), also undergoes
UPS-mediated down-regulation. Mice carrying a gene dele-
tion for Munc-18-1, exhibit loss of neurotransmitter secre-
tion during development, without affecting the initial as-
sembly of the synapse (Verhage et al., 2000). However, after
birth there is a widespread neurodegeneration with the loss
of synapses. The contribution of the UPS to this phenotype
has yet not been studied.
Protein modification by ubiquitin at nerve endings may
go beyond effects on protein degradation. Polyubiquitina-
tion targets proteins for degradation, but monoubiquitina-
tion regulates protein trafficking, involving endosomes, as
well as other functions (Hicke, 2001). Receptor tyrosine ki-
nases, such as the EGF receptor are monoubiquitinated
upon ligand binding (Haglund et al., 2003; Mosesson et al.,
2003). This leads to receptor tyrosine kinase internalization
and degradation in lysosomes, preventing recycling to the
plasma membrane. Monoubiquitination of receptor proteins
can thus exert an important control step in the action of
trophic factors. Although not yet studied in brain, this may
also occur for neurotransmitter receptors, and other mole-
cules at the synapse. It is crucial to study whether alterations
in monoubiquitination per se can affect protein trafficking
and synaptic connectivity. Wilson et al. (2002) reported re-
cently that mutation in Usp14, encoding an ubiquitin-spe-
Figure 1. The activity of the UPS and neuronal compartments. 
(A) UPS, ubiquitin proteasome system. U, ubiquitin; E1, ubiquitin 
activating enzyme; E2, ubiquitin conjugating enzyme; E3, ubiquitin 
ligase; 20S, catalytic core; 19S, regulator particle; PS. Protein substrate. 
(B) Neurons consist of three major subcellular compartments 
functionally linked to each other: the cell body, axon, and nerve 
terminals. In neurodegenerative diseases, there is an accumulation 
of mutant or misfolded proteins (circles) due to insufficient clearance 
or the relative dysfunction of the UPS. The protein aggregates can 
further disrupt the UPS and affect the axonal transport and the 
synapses. Molecular insights into axonal reactions show an involve-
ment of the UPS in axonal degeneration. In nerve endings, the UPS 
is crucial for protein turnover and synapse maintenance and function. 
The exact role of the UPS in synaptic dysfunction is not known, but 
disturbances in its activity may seriously affect protein trafficking 
and neuronal connectivity. Protein components of the UPS, including 
specific E2 and E3 molecules, and their corresponding protein targets 
may differ between compartments. This opens up the possibility for 
specific and local interference with the UPS activity under different 
conditions and in neurodegenerative diseases. 
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cific protease, causes synaptic dysfunction leading to ataxia
in mice.
In recent years, novel proteins have been discovered, such
as the ubiquitin-like proteins and those carrying ubiquitin
interacting domains that influence the efficacy of the UPS
(Weissman, 2001; Adams, 2003). So far little is known
about these proteins in the nervous system or locally in the
function of the synapse.
 
Axonal degeneration and the UPS
 
After transection, the distal segment of the nerve normally
undergoes a degeneration process with typical morpho-
logical signs, called Wallerian degeneration (Coleman and
Perry, 2002; Raff et al., 2002). This type of degeneration oc-
curs also in many neuropathies and neurodegenerative disor-
ders and is distinct from the death of the nerve cell body.
Studies of the mouse mutant, 
 
Wld
 
s
 
 that displays a signifi-
cantly slower Wallerian reaction, demonstrate that axonal
degeneration is an active process (Coleman et al., 1998;
Mack et al., 2001). In this mouse, gene rearrangements have
resulted in the production of an 85-kD chimeric protein
consisting of nicotinamide mononucleotide adenylyl trans-
ferase and the amino-terminal portion of the ubiquitination
factor E4b (Mack et al., 2001). Overexpression of the fusion
protein, using the 
 
 
 
-actin promoter or viral vectors, can de-
lay axonal degeneration (Coleman and Perry, 2002). The
data with the 
 
Wld
 
s
 
 mice suggests an involvement of the UPS
in Wallerian degeneration, but there are some caveats. Thus,
the cellular targets of the 
 
Wld
 
s
 
 chimeric gene in axonal de-
generation are not known. It has also to be shown that the
fusion protein with the truncated region of the E4 enzyme
can function in polyubiquitination and proteasome-medi-
ated degradation of proteins.
Supporting evidence for the involvement of the UPS in
axonal degeneration comes from studies of the Gracile ax-
onal dystrophy (
 
Gad
 
) mutant mice. In these mice, there is
an inactivation of the ubiquitin carboxy-terminal hydrolase,
UCH-L1, causing, among others, degeneration of the gracile
tract of the spinal cord (Saigoh et al., 1999). UCH-1 dis-
plays dual activities as a deubiquitination enzyme and as an
ubiquitin ligase (Liu et al., 2002). The exact roles of UCH-1
and the corresponding protein substrates in the 
 
Gad
 
 mice
are so far not known.
Recent studies in rats using transection of cultured neurons
or crush lesions of the optic nerve in vivo showed that inhibi-
tion of the UPS by drugs targeting the proteasome can retard
the onset of Wallerian degeneration (Zhai et al., 2003). Simi-
lar results were obtained by viral expression of an ubiquitin
protease that can reverse ubiquitination of protein substrates.
Using specific antibodies for axonal components, the frag-
mentation of microtubuli was identified as an early sign of
the axonal degeneration that was also sensitive to proteasome
inhibition (Zhai et al., 2003). These results lend credence to
the view that the local activity of UPS, acting on selective
protein targets, is important during axonal degeneration.
Further evidence comes from studies in 
 
Drosophila
 
, show-
ing that the degeneration of axons occurring during pruning
requires the UPS (Watts et al., 2003). Axon pruning is an
important process for the refinement of the neuronal con-
nections in both vertebrates and invertebrates. Studying de-
velopment of particular projecting neurons of the 
 
Drosophila
 
mushroom bodies it was shown that overexpression of an
ubiquitin protease or a mutant form of the 
 
Drosophila
 
 E1
ubiquitin-activating enzyme, inhibited pruning (Watts et
al., 2003). Likewise, mutations in two of the subunits in the
19S regulatory particle (Fig. 1 A) also impaired pruning.
This genetic evidence strongly suggests that local degenera-
tion of protein via the UPS activity is a necessary require-
ment for axon pruning during development of the mush-
room bodies. The relevance of these findings for Wallerian
degeneration and axonal reactions in neurodegenerative dis-
eases is not straightforward. However, there are similarities
between these processes both with regard to molecular
mechanisms and the cellular reactions involved. First, study-
ing different fly mutants, it was shown that axon pruning is
independent of the activity of 
 
grim
 
, 
 
hid
 
, and 
 
rpr
 
 that regulate
cell death in 
 
Drosophila
 
. This is in keeping with results ob-
tained in rodents in the 
 
Wld
 
s
 
 mice (Finn et al., 2000; Raff et
al., 2002), and shows that the programs governing axonal
degeneration and death of the nerve cell body via apoptosis
are inherently different. Second, local UPS activity seems in-
strumental for both pruning and Wallerian degeneration to
occur. Third, looking at the cellular changes, the disruption
of the microtubuli was identified as an early step in both
pruning and Wallerian degeneration. Thus, it is tempting to
suggest that the two processes may be governed by similar
mechanisms involving local regulation of axonal proteins via
the UPS.
The results on inhibition of the UPS in axons, also suggest
therapeutic targets to preserve axons after injury and in de-
generation. The caveat is that a general inhibition of protea-
some activity may be harmful to the cell. To arrive at a spe-
cific inhibition of the UPS, the exact nature of the different
molecules involved in ubiquitination and degradation of
protein targets in the axons needs to be studied in more de-
tail. The first attempt toward this was made by Watts et al.
(2003) in 
 
Drosophila
 
. However, of the over a dozen of E2
and E3 enzymes studied, none was found important for
axon pruning. This does not come as a surprise in view of
the fact that in 
 
Drosophila
 
, as in mammalian cells the diver-
sity of these enzymes and their corresponding protein sub-
strates is large. However, the use of modern large-scale tech-
niques for proteome analysis may provide new insights into
these important questions.
 
Concluding remarks
 
Synaptic dysfunction and decreased connectivity herald
many of the neurodegenerative diseases. The UPS play an
important role in synaptic function and may contribute to
the disease-induced changes. The activity of the UPS is in-
volved in local axonal degeneration after nerve injury. The
mechanisms controlling axonal degeneration are different
from those regulating death of the nerve cell body. One
could then envision a two-stage approach in neurodegenera-
tion with treatments of the axon and the soma separately.
However, with regard to such therapies and the effects of re-
ducing UPS activity, there is a 
 
Scylla and Charybis
 
 situation
for these two compartments. Inhibition of local UPS activity
is beneficial for retarding axonal degeneration. However, a
drawback is that there is already a relative inhibition of the 
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UPS in the neurological disorders, caused by protein aggre-
gates and toxic products in the cell (Fig. 1 B). A further inhi-
bition of the UPS may thus aggravate the underlying disease.
Although one could foresee a local delivery of UPS inhibi-
tors, this may prove cumbersome. Many of the compounds
used to date are also rather toxic and show unspecific effects.
To circumvent these problems, we need to know more
about the occurrence and the nature of molecules, including
specific E2 and E3 enzymes and the corresponding protein
substrates in the neuron. Such information may allow de-
signing novel drug targets to influence the UPS separately in
the axon and the nerve cell body in different diseases. Given
the current interest in the UPS, increased knowledge on
these matters is likely to occur rapidly. The door to new dis-
coveries in this field is now more than ajar.
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